TROP2-ADCs, hallmarked by SG and DXd constructs (both containing potent topoisomerase I payloads), demonstrated significant tumor response across both platinum-sensitive and platinum-resistant SCLC. The gene discussed is TACSTD2; the disease is neoplasm.